ArticleScientific reports2025
Integration of Single-cell and bulk RNA sequencing data uncovers lymphatic metastasis-related prognostic genes and a predictive model in bladder cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bladder cancer (BLCA) exhibits considerable heterogeneity, and research into its tumor microenvironment and prognostic biomarkers remains insufficient. This study aims to identify key prognostic genes and immune microenvironment factors to enhance clinical assessment. Primary tumor (PT) and lymph node metastasis (LNM) samples were obtained from patients with BLCA, and single-cell RNA sequencing (scRNA-seq) was conducted to analyze cellular composition and functional variations. Prognostic genes were identified based on integrated bulk transcriptomic data, leading to the development of a risk model. Functional enrichment analyses further elucidated the molecular characteristics of high- and low-risk cohorts. The scRNA-seq analysis revealed significantly elevated metabolic activity in epithelial cells of LNM. A subpopulation of epithelial cells, defined by 133 characteristic genes, was identified as pivotal in the lymphatic metastasis of BLCA. The prognostic model, derived from nine key genes (APOL1, CAST, DSTN, SPINK1, JUN, S100A10, SPTBN1, HES1, and CD2AP), demonstrated robust predictive performance. Functional enrichment analysis indicated that the high-risk group predominantly activated extracellular matrix (ECM) receptor interactions and the complement pathway, while the low-risk group was primarily associated with carbohydrate metabolism pathways. This study provides insights into the tumor heterogeneity and immune microenvironment of BLCA, introduces a high-precision prognostic model, and establishes a novel theoretical basis for personalized BLCA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.